Want to see FBLG full AI Analyst Report?
FBLG Stock Chart & Stats
$1.41
-$0.08(-11.92%)
At close: 4:00 PM EDT
$1.41
-$0.08(-11.92%)
Day’s Range― - ―
52-Week Range$0.62 - $12.78
Previous Close$0.67
Volume161.72K
Average Volume (3M)978.93K
Market Cap
$9.59M
Enterprise Value$3.89
Total Cash (Recent Filing)$3.52M
Total Debt (Recent Filing)$1.46M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 17, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.00
Shares Outstanding6,658,193
10 Day Avg. Volume1,423,641
30 Day Avg. Volume978,931
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside325.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet DeleveragingSharp debt reduction and positive equity improve capitalization and reduce interest and refinancing pressure. This gives FibroBiologics a stronger financial base while it advances its clinical pipeline, although operating losses still consume resources.
Scientific And Strategic Board ExpertiseBoard additions bring expertise in genomics, infectious disease, biomedical science, longevity and strategic networks. Stronger scientific and governance capabilities may support clinical translation, partnerships and long-term positioning in chronic disease therapies.
Additional Development FundingThe financing supplies immediate working capital for general corporate purposes and pipeline advancement. Warrants may provide additional proceeds if exercised, giving the company some funding flexibility as it continues research, manufacturing and regulatory activities.
Bears Say
No Revenue And Persistent LossesFibroBiologics remains pre-commercial, with no revenue to offset rising development costs and large recurring losses. Until a candidate reaches commercialization, profitability depends on successful clinical progress and continued access to external capital.
Sustained Cash Burn And Funding DependencePersistent operating and free-cash-flow deficits indicate that internal cash generation cannot currently fund the business. Continued research and regulatory spending will likely require further financing, creating dilution, execution and liquidity risks.
Nasdaq Listing Compliance RiskA potential loss of Nasdaq listing could reduce institutional access, liquidity and financing flexibility, while increasing operational and reputational friction. The appeal outcome is uncertain, leaving a material structural risk to the company’s capital markets access.
FibroBiologics, Inc. News
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $0.62 and its highest was $12.78 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
FibroBiologics, Inc.’s market cap is $9.59M.
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 76 days.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on Jul 31, 2026. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.93 by $0.27.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -0.63.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 6,658,193 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.93. Following the earnings report the stock price went up 12.857%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Currently, no hedge funds are holding shares in FBLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
FBLG Stock 12 Month Forecast
Average Price Target
$6.00
▲(325.53% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Curis
―
Synlogic
―
Lexaria Bioscience
―
Processa Pharmaceuticals
―
Ownership Overview
94.16% Insiders
1.04% Mutual Funds
2.42% Other Institutional Investors
1.96% Public Companies and
Individual Investors